Cytokinetics (CYTK) PT Raised to $33 at Piper Sandler, After Licensing Collaboration Announced
Piper Sandler analyst Edward A. Tenthoff raised the price target on Cytokinetics (NASDAQ: CYTK) to $33.00 (from $28.00) while maintaining a Overweight rating.